Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: New Investigator Award - PA: HIV/AIDS Biomedical/Clinical Research

McGill University

$60,000.00

The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic.

EF 2008-09

Résumé
APOBEC3G is a host factor that is able to inhibit HIV-1 replication. A HIV-1 protein, so-called Vif, can protect the virus from the attack of APOBEC3G by binding to APOBEC3G and subsequently destroying it. Understanding the mechanism of how Vif protects HIV-1 from the inhibtion by APOBEC3G may lead us to develop a novel therapeutic strategy for HIV-1 infection. The objective of this work is to explore the mechanism by which Vif abolishes anti-HIV activity of APOBEC3G.
Programme
New Investigator Award - PA: HIV/AIDS Biomedical/Clinical Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
176402
Name
Cen Shan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
New Investigators C
Projecttitle
The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic.
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
New Investigator Award - PA: HIV/AIDS Biomedical/Clinical Research
Keyworddelim
Aids; Apobec Superfamily; Apobec3g; Assembly; Deaminase; Encapsidation
Abstract
APOBEC3G is a host factor that is able to inhibit HIV-1 replication. A HIV-1 protein, so-called Vif, can protect the virus from the attack of APOBEC3G by binding to APOBEC3G and subsequently destroying it. Understanding the mechanism of how Vif protects HIV-1 from the inhibtion by APOBEC3G may lead us to develop a novel therapeutic strategy for HIV-1 infection. The objective of this work is to explore the mechanism by which Vif abolishes anti-HIV activity of APOBEC3G.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cen, Shan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,000~ $0~